Brock L Schweitzer

6PUBLICATIONS
64CO-AUTHORS
Instrumental methods (excl. immunological and bioassay methods)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 11, 2026
High Concordance between ddPCR- and NGS-Based Quantification of Donor-Derived Cell-Free DNA Percentage after Kidney Transplantation.

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

|Apr 06, 2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.

Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz

|Feb 22, 2023
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.

Tyler J Nielsen, Matthew G Varga, Catherine T Cronister

|Mar 16, 2022
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.

Hiroko Masuda, Kenichi Harano, Sakiko Miura

|May 01, 2020
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.

Jose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee

Pageof 1

Frequent Collaborators

5 joint publications

Robert Seitz

4 joint publications

Tyler J Nielsen

2 joint publications

Douglas Teller Ross

2 joint publications

Matthew Gordon Varga